ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML. Licensed from Almirall in 2013, we have global rights for all non-topical and non-dermatological indications. AML is a cancer of the myeloid line of blood cells, characterised primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. We are conducting a Phase 2 clinical trial to develop ASLAN003 in AML. We are also exploring other solid tumour types where DHODH may be relevant, such as TNBC and HCC.
ASLAN003 has the potential to be a first-in-class DHODH inhibitor in oncology due to the following competitive advantages:
ASLAN has partnered with Almirall for the development of ASLAN003. Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM).
To learn more about Almirall, please visit www.almirall.com